A phase II clinical trial of a COVID-19 vaccine candidate, conducted in China, has found that it is safe and induces an immune response, a study published in The Lancet says.

Scientists, including those from the Chinese Centre for Disease Control and Prevention, said the results provide data from a wider group of participants than their phase I trial, including a small sub-group of participants aged over 55 years.